

Clinical phenotype and management of sound-induced pain: Insights from adults with pain hyperacusis

Kelly N. Jahn^{a,b*}, Sean Takamoto Kashiwagura^{a,b}, Muhammad Saad Yousuf^{c*}

^a Department of Speech, Language, and Hearing, The University of Texas at Dallas, Richardson, TX, USA

^b Callier Center for Communication Disorders, The University of Texas at Dallas, Dallas, TX, USA

^c Department of Neuroscience and Center for Advanced Pain Studies, The University of Texas at Dallas, Richardson, TX, USA

* Corresponding authors

ABSTRACT: Pain hyperacusis, also known as noxacusis, causes physical pain in response to everyday sounds that do not bother most people. How sound causes excruciating pain that can last for weeks or months in otherwise healthy individuals is not well understood, resulting in a lack of effective treatments. To address this gap, we identified the most salient physical and psychosocial consequences of debilitating sound-induced pain and reviewed the interventions that sufferers have sought for pain relief to gain insights into the underlying mechanisms of the condition. Adults ($n = 32$) with pain hyperacusis attended a virtual focus group to describe their sound-induced pain. They completed three surveys to identify common symptoms and themes that defined their condition and to describe their use of pharmaceutical and non-pharmaceutical therapies for pain relief. All participants endorsed negative effects of pain hyperacusis on psychosocial and physical function. Most reported sound-induced burning (80.77%), stabbing (76.92%), throbbing (73.08%), and pinching (53.85%) that occurs either in the ear or elsewhere in the body (i.e., referred pain). Participants reported using numerous pharmaceutical and non-pharmaceutical interventions to alleviate their pain with varying degrees of pain relief. Benzodiazepines and nerve blockers emerged as the most effective analgesic options while non-pharmaceutical therapies were largely ineffective. Symptoms of pain hyperacusis and therapeutic approaches are largely consistent with peripheral mechanistic theories of pain hyperacusis (e.g., trigeminal nerve involvement). An interdisciplinary approach to clinical studies and the development of animal models is needed to identify, validate, and treat the pathological mechanisms of pain hyperacusis.

1 INTRODUCTION

2 Approximately 15% of adults [6] and 17% of children [15] suffer from hyperacusis, a
3 disorder characterized by an inability to tolerate ordinary sounds that do not bother most people
4 [19]. Some individuals perceive everyday sounds to be excessively loud (i.e., *loudness*
5 *hyperacusis*), whereas others experience physical pain in response to sounds (i.e., *pain*
6 *hyperacusis* or *noxacusis*) [19]. The relative prevalence of these two hyperacusis subtypes is
7 unknown, but a recent survey demonstrated that 62.5% of adults with hyperacusis experience
8 some level of sound-induced physical pain [21]. Individuals with pain hyperacusis often present
9 with a relatively severe clinical phenotype, wherein they report frequent “setbacks” (i.e.,
10 symptom exacerbations in response to a trigger sound) and reduced benefit from behavioral
11 interventions (e.g., sound therapy) [21]. Despite the severity of pain hyperacusis, healthcare
12 professionals have limited tools to diagnose, monitor, and treat the condition [2] and they do not
13 widely recognize the pain hyperacusis phenotype [7].

14 A primary reason for the lack effective clinical tools for pain hyperacusis is that the
15 underlying mechanisms of sound-induced pain remain elusive [6]. Existing theories of the neural
16 underpinnings of pain hyperacusis implicate structures ranging from the middle ear to the inner
17 ear to the central auditory pathway (**Figure 1**). Middle ear models of sound-induced pain broadly
18 suggest that overload, damage, or myoclonus of the tensor tympani muscle can irritate the
19 trigeminal nerve and cause pain in or near the ear [12,20]. Others have shown that Type-II
20 cochlear afferents share similar morphological and neurochemical properties with nociceptive
21 somatic C fibers and may transmit damage-evoked pain signals from the inner ear to the central
22 nervous system (CNS) [4,10,22]. Finally, a large body of basic science literature demonstrates
23 that damage to the peripheral auditory system leads to a cascade of downstream changes that

24 elicit abnormally elevated neural activity along the central auditory pathway and which may lead
25 to perceptual hypersensitivity in rodents [1].

26 Existing conceptual frameworks of the biological underpinnings of pain hyperacusis lack
27 empirical evidence from humans, relying largely on theory [12,20] or animal models [1,22].
28 Consequently, pain hyperacusis remains poorly treated and responds inadequately to existing
29 therapies, highlighting the urgent need for more effective solutions. We surmise that the
30 mechanisms of pain hyperacusis will continue to remain elusive without a thorough
31 understanding of how the condition manifests physically and the types of interventions that can
32 alleviate sound-induced pain. Here, we used a participatory research method to generate a
33 conceptual framework for understanding the most salient symptoms of pain hyperacusis from the
34 perspective of individuals who suffer from the condition. We also identified pharmaceutical and
35 non-pharmaceutical interventions that the participants have tried and the perceived efficacy of
36 each. We aimed to characterize the specific physical and psychosocial consequences of sound-
37 related pain and to generate a preliminary dataset to identify interventions that may provide pain
38 relief. These data will be used to develop targeted clinical trials aimed at identifying effective
39 treatments for pain hyperacusis which, in turn, will aid in uncovering the underlying mechanisms
40 of this condition in humans.

41

42 METHODS

43

44 *Participants*

45 This study was approved by the Institutional Review Board of The University of Texas at
46 Dallas (IRB-23-200) and all participants provided written informed consent to participate. A

47 snowball sampling technique was used to recruit prospective participants, and recruitment flyers
48 were posted online on our laboratory website, social media (Facebook, Instagram, and
49 Twitter/X), and a research recruitment registry (ResearchMatch.org). A total of 32 fluent English-
50 speaking adults (age 19-65 years, mean age = 37 years, 11 female) who self-reported that they
51 experience physical pain when they hear sounds participated. All participants had experienced
52 pain hyperacusis for at least one year (range 1 to 27 years). Other self-reported co-morbid
53 audiovestibular, neurological, mental health, and chronic pain conditions are listed in **Table 1**.

54

55 *Procedures*

56 We first used a modified concept mapping approach to identify the key symptoms and
57 experiences associated with sound-induced pain [3,17]. Concept mapping is a participatory
58 research method that combines qualitative and quantitative techniques to develop a conceptual
59 framework for how stakeholders (here, adults with pain hyperacusis) experience a particular
60 phenomenon. The concept mapping portion of the study consisted of three primary stages
61 (brainstorming, rating, and sorting), outlined in the following sections. We also disseminated a
62 survey to comprehensively characterize the pharmaceutical and non-pharmaceutical
63 interventions that these participants have tried, and the perceived effectiveness of each
64 intervention.

65

66 *Concept Mapping Stage 1: Brainstorming (Virtual Focus Group)*

67 The purpose of the concept mapping brainstorming stage is to generate a set of statements
68 that represent the conceptual domain for the topic of interest from the perspective of stakeholders
69 themselves [18]. In the present study, participants ($n = 26$) joined a 60-minute virtual focus group

70 held on the Microsoft Teams platform. During the session, the participants were asked to
71 generate as many statements as possible describing: 1) Characteristics of their sound-related
72 pain, and 2) Symptoms related to sound sensitivity or hyperacusis.

73 Some participants with severe pain hyperacusis were unable to speak or listen to others'
74 voices, so we offered multiple accommodations to ensure that all participants had equal
75 opportunity to respond to the focus prompts. Participants were allowed join the focus group with
76 or without audio and we provided instructions for utilizing automatically generated closed
77 captions. Additionally, participants could elect to respond to the focus prompts via either spoken
78 word or text. The Microsoft Teams meeting was recorded so that verbal responses could be
79 transcribed after the session. To facilitate text-based communication, participants received a
80 private link to a Google Docs document to respond to the focus prompts in real time. They were
81 also allowed to enter comments or questions into the Microsoft Teams chat box. All participants
82 had access to the focus prompts during the entire session and were able to freely respond and
83 view other participant responses. Participants were allowed to share additional information about
84 their experiences via email after the focus group.

85 After the session, the research team reviewed all written and verbal responses. We
86 eliminated redundant ideas and condensed the responses into a set of 92 statements that
87 encompassed all unique ideas generated during the focus group (**Table 2**). The resulting set of 92
88 statements served as the content for the next two stages of the study (i.e., rating and sorting
89 tasks).

90

91 *Concept Mapping Stage 2: Rating the Statements*

92 The purpose of the concept mapping rating stage is to allow participants to rate each
93 statement on a dimension of interest to indicate how much the statement embodies their overall
94 experience with the topic [18]. It is possible that some symptoms and consequences of pain
95 hyperacusis are more common than others. Thus, the goal of the rating task in this study was to
96 determine how common it is for an individual with pain hyperacusis to experience each of the
97 symptoms discussed during the focus group. Participants ($n = 26$) completed an online survey
98 where they viewed all 92 statements and rated how well each statement applied to their own
99 personal experience with pain hyperacusis. Twenty of these participants had attended the focus
100 group, and 6 were new participants who were unable to attend the focus group. They received a
101 private link to a Qualtrics survey, where each statement was displayed in random sequence
102 alongside a 5-point Likert scale. Most statements (78 out of 92) were rated on a scale with
103 response choices of *Never*, *Sometimes*, *About Half the Time*, *Most of the Time*, and *Always*. For
104 clarity, a scale with response choices of *Strongly Disagree*, *Somewhat Disagree*, *Neither Agree*
105 *nor Disagree*, *Somewhat Agree*, and *Strongly Agree* was used for 14 statements [Statement
106 numbers S79-S92; see Table 2] due to their linguistic structure.

107

108 *Concept Mapping Stage 3: Sorting the Statements*

109 The purpose of the concept mapping sorting stage is to identify interrelationships, or
110 themes, amongst the statements [18]. Individuals that completed the rating task were invited to
111 complete a follow-up activity where they viewed all 92 statements for a second time and sorted
112 the statements into categories based on perceived similarities between the statements. The goal
113 of this task was to assist the research team in identifying categories and themes within the data.
114 Participants received a private link to view and sort the statements within OptimalSort – Card

115 Sorting software (Optimal Workshop Ltd.). Participants were instructed to organize the
116 statements into categories in a way that made sense to them based on thematic similarity. They
117 were instructed to sort each statement into a category, regardless of whether the statement
118 applied to their own personal situation, and that they should not create a “does not apply”
119 category. They were told that a statement could be placed in its own category if it was unrelated
120 to other statements, but they should not create “miscellaneous” or “other” categories. Once a
121 participant sorted all statements into categories, they were prompted to name each category that
122 they created. Twenty-five participants initiated the sorting task. Of those 25 participants, four did
123 not sort all 92 statements into a category and six created a “does not apply” category despite
124 instructions to the contrary. The categories generated by the remaining 15 participants were used
125 in subsequent analyses. Note that 15 is a sufficient sample size for the sorting stage of a concept
126 mapping study, as the goal of this task is primarily to guide the experimenters in identifying
127 conceptual themes in the data [18].

128

129 *Intervention Survey*

130 After the concept mapping portion of the study, we disseminated a survey to determine
131 whether these participants had tried any pharmaceutical or non-pharmaceutical interventions for
132 pain hyperacusis and, if so, whether those treatments were effective at alleviating their sound-
133 induced pain. Twenty-four participants completed the follow-up survey. Participants were asked
134 to indicate whether they have ever used opioid, non-opioid prescription or over-the-counter
135 medications, oral or inhaled cannabinoids (marijuana, THC, and/or CBD), Botox injections, or
136 non-pharmaceutical interventions for pain hyperacusis. If they answered “yes” to any of those
137 questions, they viewed a list of relevant medications or interventions and selected all that they

138 had tried. Each question had an open-ended “Other” option for choices that were not listed. For
139 each intervention selected, participants were asked to indicate whether it helped, hurt, or had no
140 effect on their pain hyperacusis using a 5-point Likert scale with the following options: *Excellent*
141 *effect (>90% pain relief)*, *Modest effect (75% pain relief)*, *Somewhat effective (50% pain relief)*,
142 *No effect (0% pain relief)*, *Made my noxacusis worse*. For each non-pharmaceutical intervention,
143 participants were asked to describe who administered the treatment (e.g., self-administered,
144 licensed professional).

145

146 *Data analysis*

147 Data were analyzed in R (Version 4.2.2) and MATLAB (MathWorks, Inc., Natick, MA).
148 Responses from the sorting task were analyzed using multidimensional scaling and hierarchical
149 cluster analyses. A symmetric 92 X 92 similarity matrix was generated for each participant that
150 indicated which statements they grouped together during the sorting task. The individual
151 similarity matrices were added together to produce a total similarity matrix, which indicated how
152 many participants in the entire sample grouped the same two statements together. The total
153 similarity matrix was transformed into a matrix of Euclidean distances using the MATLAB *pdist*
154 function. Statements that were grouped together more frequently by participants are closer
155 together in Euclidean space (i.e., they have a smaller Euclidean distance) than statements that
156 were grouped together less frequently.

157 Using the MATLAB *cluster* function, the Euclidean distances were submitted to a
158 hierarchical cluster analysis to group individual statements into clusters of statements that
159 reflected similar concepts [17]. The maximum number of clusters was first selected based on the
160 average number of categories that the participants created (Mean = 12 categories, Range = 3-26

161 categories). The research team reviewed the statements within the 12 clusters and discussed
162 whether it was appropriate to increase or decrease the number of clusters to better categorize the
163 subjective data [5]. After examining five possible cluster solutions, two of the authors (KNJ and
164 STK) reached a consensus that 17 clusters provided a reasonable level of specificity based on the
165 subjective content matter. The clusters represented 17 different concepts or themes within the
166 data. The authors named each of the 17 clusters with guidance from the category labels that the
167 participants generated during data collection (**Table 2**).

168 Participants' rating scores were used to identify the relative importance of each cluster
169 and each statement to the pain hyperacusis experience. This was determined by performing two
170 separate analyses. Point values were assigned to the Likert scale response choices as follows: 1 =
171 *Never*, 2 = *Sometimes*, 3 = *About Half the Time*, 4 = *Most of the Time*, and 5 = *Always* and 1 =
172 *Strongly Disagree*, 2 = *Somewhat Disagree*, 3 = *Neither Agree nor Disagree*, 4 = *Somewhat*
173 *Agree*, and 5 = *Strongly Agree*. To identify the most salient clusters, the rating scores were
174 averaged across all participants and across all statements within each cluster. Clusters with
175 higher average ratings were interpreted as more common to the lived experience of pain
176 hyperacusis than clusters with lower average ratings.

177 For individual statements, we also calculated the percentage of participants that provided
178 each Likert scale response. Any response other than "Never" or "Strongly Disagree" was
179 considered an endorsement of the corresponding statement (i.e., the person experiences the
180 symptom at least sometimes or agrees with the statement at least some of the time). Statements
181 that were endorsed by a higher percentage of participants were interpreted as more common to
182 the lived experience of pain hyperacusis than statements that were endorsed by a lower
183 percentage of participants.

184

185 RESULTS

186 *Concept Mapping*

187 Hierarchical cluster analyses revealed a 17-cluster solution that described the most salient
188 characteristics and consequences of sound-induced pain generated during the focus group (**Table**
189 **2**). The 17 clusters arranged in order from highest-to-lowest average rating are: *Lack of Empathy*
190 *or Support from Others*; *Isolation and Reduced Physical Activity*; *Symptom Setbacks*; *Mental*
191 *Health Consequences*; *Pain Triggers, Severity, and Time course*; *Control and Avoidance*
192 *Behaviors*; *Pain Laterality*; *Emotional Reactions to Sound*; *Symptom Onset*; *Neuropathic Pain*;
193 *Fluctuating Severity*; *Otologic Symptoms (Non-pain)*; *Interference with Essential Functions*;
194 *Other Sensory Sensitivities*; *Irritation/Inflammation*; *Referred Pain*; and *Head Sensations*. The
195 average ratings for each cluster ranged from 1.66 for *Head Sensations* (least common across all
196 participants) to 4.21 for *Lack of Empathy or Support from Others* (most common across all
197 participants). Table 2 lists the 17 clusters, the average rating for each cluster, the individual
198 statements within each cluster, the average rating for each statement, and the percentage of
199 participants who endorsed each statement at least sometimes.

200 **Figure 2** shows the percentage of participants who endorsed each statement related to the
201 quality and location of their pain (i.e., clusters describing *Neuropathic Pain* and *Referred Pain*)
202 along with a visual schematic of those data. The pain was most often described as a burning
203 (80.77%), stabbing (76.92%), throbbing (73.08%), or pinching (53.85%) sensation. Although
204 92.31% of participants reported that the pain can occur in or near their ears, less than half of
205 participants (42.31%) indicated that this was “Always” the case. Many participants reported
206 referred pain in addition to pain in or near the ears, including pain in the face (73.08%), head

207 (side – 57.69%, back – 42.31%, front – 30.77%), throat (34.62%), neck (53.85%), and elsewhere
208 in the body (46.15%; i.e., outside the head and neck region). More than half of participants
209 indicated that their sound-related pain can change locations (65.38%) and that the quality and
210 severity of the sound-related pain can fluctuate (**Table 2**, *Fluctuating Severity* cluster).

211 In addition to the physical characteristics of the pain itself, participants consistently
212 reported experiencing setbacks after sound exposure (**Table 2**, *Symptom Setback* cluster) and
213 described common triggers and factors that influence the severity and temporal characteristics of
214 the pain (**Table 2**, *Pain Triggers, Severity, and Time Course* cluster). We also note that although
215 80.77% of the participants endorsed bilateral sound-related pain, many reported unilateral pain
216 (46.15%) or symptoms that are asymmetric in severity (84.62%) (**Table 2**, *Pain Laterality*
217 cluster). A smaller, but noteworthy, percentage of participants endorsed symptoms such as
218 inflammation (61.54%), itchiness (73.08%), or redness (30.77%) near the site of their sound-
219 related pain and other head-related sensations such as fullness/pressure (61.54%), migraines
220 (30.77%), dizziness (30.77%), or nausea (26.92%) associated with sound exposure (**Table 2**).

221 As hyperacusis is often considered to be a disorder of the ear, we were interested in
222 understanding what other otologic and sensory symptoms these individuals may experience
223 (**Figure 3; Table 2**). Almost all participants (96.15%) experience tinnitus (perception of phantom
224 sounds), and their tinnitus is often reactive (88.46%) (i.e., exacerbated by the presence of
225 external sounds) (Figure 3A). Most participants reported additional, non-pain sensations in the
226 ear such as fullness or pressure (80.77%), fluttering (80.77%), pulsing (65.38%), and vibrations
227 (57.69%) and other sensory sensitivities (53.85%) (**Figure 3; Table 1**).

228 In addition to describing physical and sensory symptoms, participants often discussed the
229 emotional and psychosocial consequences of pain hyperacusis. Clusters related to emotional and

230 psychosocial symptoms were highly rated across participants, suggesting that these experiences
231 may be more consistent than the physical manifestation of the pain itself. **Figure 4** shows the
232 percentage of participants who endorsed a lack of empathy or support from others, which was the
233 highest-rated cluster. All participants reported that individuals within their social network do not
234 understand their hyperacusis symptoms, with 100% endorsing this concept for family and
235 friends, and 96.15% indicating that medical and healthcare professionals do not understand their
236 symptoms (**Figure 4; Table 2**).

237 **Figure 5** shows the percentage of participants who endorsed each statement within the
238 top two emotional and psychosocial clusters (i.e., *Isolation and Reduced Physical Activity* and
239 *Mental Health Consequences*). Every participant indicated that their lifestyle has changed
240 significantly since the onset of their hyperacusis, with the vast majority endorsing all statements
241 related to isolation and reduced physical activity (range 84.62% to 100%) and mental health
242 concerns (range 88.46% to 96.15%) (**Figure 5; Table 2**). To manage their symptoms, most of the
243 participants use control and avoidance techniques such as wearing hearing protection devices
244 (96.15%) and planning their lifestyle to avoid sound exposure (100%) (**Table 2**).

245

246 *Intervention Survey*

247 Overall, participants unanimously reported pain sensations (**Figure 2**; e.g., burning,
248 stabbing, pinching) that are consistent with possible damage, disease, or dysfunction of one or
249 more peripheral nerves. We created and disseminated a survey to identify potential treatment
250 response patterns that could shed light on the underlying mechanisms of pain hyperacusis in
251 humans. Participants reported that they have tried a variety of treatments to alleviate sound-
252 induced pain, with most participants (87.50%, $n = 21$) having tried both pharmaceutical and non-

253 pharmaceutical therapies (**Figure 6, Table 3**). The average participant reported using 4.88
254 different therapies (range 0 to 12), with 58.33% ($n = 14$) trying multiple pharmaceuticals and
255 66.67% ($n = 16$) trying multiple non-pharmaceutical therapies (**Figure 6**).

256 Those who use pharmaceuticals reported the following drugs, in descending order of
257 frequency: oral or inhaled cannabinoids (e.g., marijuana, THC, and/or CBD) ($n = 10$),
258 benzodiazepines (e.g., clonazepam, alprazolam) ($n = 10$), antidepressants (e.g., clomipramine,
259 amitriptyline, duloxetine) ($n = 9$), non-steroidal anti-inflammatory drugs (NSAIDs; e.g.,
260 ibuprofen, naproxen) ($n = 8$), muscle relaxants (e.g., baclofen, cyclobenzaprine) ($n = 6$),
261 anticonvulsants (e.g., gabapentin, pregabalin, carbamazepine) ($n = 6$), nerve blockers (e.g.,
262 lidocaine, ambroxol) ($n = 4$), oxycodone ($n = 1$), and Botox injections ($n = 1$). Of the respondents
263 who selected “Other”, two reported using Tylenol, one reported Tramadol (opioid), one reported
264 flunarizine, and one reported valacyclovir.

265 The perceived effectiveness of these pharmaceutical interventions varied (**Figure 6**). Out
266 of the 63 effectiveness ratings provided across all pharmaceutical interventions, 55.56% ($n = 35$)
267 of the ratings indicated that the treatment had no effect on pain hyperacusis (0% pain relief) and
268 3.17% ($n = 2$) indicated that the treatment made their pain hyperacusis worse (3.17%, $n = 2$).
269 Some patients reported modest-to-excellent effects (75-100% pain relief) from benzodiazepines
270 ($n = 3$), nerve blockers ($n = 2$), anticonvulsants ($n = 2$), Tylenol ($n = 1$), oxycodone ($n = 1$), and
271 Botox ($n = 1$). The one participant who tried Botox reported that the excellent effect (100% pain
272 relief) was experienced after injection into the tensor veli palatini muscle. That participant
273 previously received Botox injections in the masseter, occipital muscles, and temporal muscles
274 with limited effect. Two other participants reported that they are currently seeking off-label

275 Botox injections for pain hyperacusis. Cannabinoids were consistently rated as ineffective for
276 pain relief ($n = 9$), with one participant indicating that they made their pain hyperacusis worse.

277 Use and perceived effectiveness of non-pharmaceutical interventions were also highly
278 variable (**Figure 6**). Respondents who tried non-pharmaceutical interventions reported the
279 following treatments, in descending order of frequency: meditation, yoga, or mindfulness therapy
280 ($n = 12$), counseling ($n = 11$), cognitive behavioral therapy ($n = 9$), sound therapy ($n = 8$), and
281 tinnitus retraining therapy ($n = 5$). The respondents who selected “Other” reported round and
282 oval window reinforcement surgery ($n = 1$), low-level laser therapy ($n = 1$), pranic healing and
283 energy healing ($n = 1$), TMJ-specific splints or physical therapy ($n = 3$), chiropractic or massage
284 therapy ($n = 2$), dry needling and acupuncture ($n = 1$), and prayer ($n = 1$). It was noted that nine
285 participants self-administered at least one of these non-pharmaceutical treatments instead of
286 following a prescriptive protocol administered by a professional.

287 Non-pharmaceutical interventions were largely ineffective at providing pain relief in our
288 cohort. Out of the 57 efficacy ratings provided across all non-pharmaceutical interventions, most
289 indicated that these treatments had no effect on pain hyperacusis (0% pain relief) (66.67%, $n =$
290 38) or that these interventions made their noxacusis worse (10.53%, $n = 6$). All six participants
291 who experienced a worsening of their noxacusis indicated that this occurred after therapies that
292 involved a sound exposure component (i.e., sound therapy or tinnitus retraining therapy). Only a
293 few patients reported modest-to-excellent effects (>75% pain relief) of cognitive behavioral
294 therapy ($n = 1$), sound therapy ($n = 2$), TMJ-specific treatments ($n = 2$), and chiropractic or
295 massage therapy ($n = 1$).

296

297

298

299 DISCUSSION

300 *Physical Characteristics of Sound-Induced Pain*

301 We interviewed adults with severe pain hyperacusis about their experiences, and used
302 their responses to generate follow-up surveys that targeted the primary features of sound-induced
303 pain, other pertinent symptoms, and possible interventions. This study differs from previous
304 work [21] in that we focused solely on individuals with severe pain hyperacusis, allowed them to
305 self-describe the symptoms and experiences that are most important to their quality of life, and
306 collected detailed information about interventions and perceived effectiveness. Identifying the
307 type of pain associated with pain hyperacusis is crucial for appropriate pain management, since
308 the therapeutic approaches can vary drastically. Most participants reported physical sensations
309 consistent with neuropathic pain (i.e., burning, stabbing, throbbing, pinching) that can be
310 accompanied by irritation or inflammation of the nerve near the pain site. The pain often
311 fluctuates in severity, location, and quality, and it can occur immediately after a sound exposure,
312 or it can be delayed by several hours. Even though hyperacusis is generally thought to be an ear
313 disorder and many participants had co-morbid otologic symptoms (e.g., tinnitus, aural fullness),
314 they often reported referred pain (i.e. pain that is not restricted to the ear) and non-otologic
315 sensory sensitivities (e.g., light, touch). Many of these symptoms are consistent with a recent
316 report that surveyed individuals with pain hyperacusis and loudness hyperacusis [21].

317 Most of our participants attributed the onset of their pain hyperacusis to high-intensity
318 noise exposure or ototoxic substances (**Table 2**). Rodent models demonstrate that acoustic
319 overexposure and ototoxicity facilitate a paradoxical increase in sound-evoked and spontaneous
320 neural activity in the central auditory system [1]. This enhanced central gain following sensory
321 loss is believed to underlie the generation of hyperacusis and tinnitus. While basic science work

322 shows abnormally elevated central auditory gain following acoustic injury, there is little-to-no
323 empirical evidence to support central gain as the underlying cause of pain hyperacusis per se.
324 The behaviors evaluated in rodent models may be interpreted as correlates of elevated loudness
325 perception or hyper-reactivity, but it is unclear whether those rodents experience sound-induced
326 pain. It should also be noted that a large body of literature supports a gradual increase in central
327 auditory gain with advancing age [13], yet older adults do not typically develop sound-induced
328 pain as part of the normal aging process. In the present study, most participants reported low
329 efficacy of interventions that are designed to counteract maladaptive gain in the CNS (e.g., sound
330 therapy, tinnitus retraining therapy, benzodiazepines) and seven participants reported that those
331 therapies made their noxacusis worse.

332 The most pertinent symptoms that our patients report (e.g., neuropathic pain,
333 inflammation, irritation, referred pain, and other otologic symptoms) suggest that the origin of
334 pain hyperacusis may be peripherally mediated as suggested by middle and inner ear models
335 (**Figure 1**). Approximately 95% of the auditory nerve is comprised of myelinated Type-I neurons
336 that carry acoustic information from the inner hair cells (IHCs) to the cochlear nucleus in the
337 brainstem. The remaining 5% of auditory nerve fibers are unmyelinated Type-II neurons that
338 contact outer hair cells (OHCs). Previous work suggests that Type-II afferents may be involved
339 in auditory nociception, as these fibers have similar morphologic and neurochemical properties
340 to pain-sensing C fibers in the somatic nervous system [4,10,23]. Specifically, both types of
341 fibers can be activated by adenosine triphosphate (ATP), a pain-signaling molecule that is
342 released by damaged tissue, including the OHCs [4,10,23].

343 Although it is possible that Type-II cochlear afferents could signal tissue damage within
344 the cochlea, damage-evoked activity in these neurons has yet to be linked to perceptual outcomes

345 and it is unclear how this mechanism alone would account for the referred pain and non-pain
346 sensations (e.g., aural fullness, pressure, fluttering, muscle spasms) that our participants report.
347 Instead, it has been hypothesized that overload or damage to the tensor tympani muscle (TTM) in
348 the middle ear can lead to pain that spreads via inflammatory processes to activate the trigeminal
349 nerve and generate symptoms consistent with neuropathic pain and other otologic symptoms
350 [12]. The trigeminal nerve transmits sensory information from the middle ear to the
351 trigeminocervical complex (TCC) in the brainstem and then to the cortex. The TCC integrates a
352 variety of sensory and nociceptive inputs from the middle ear, head, and neck regions, providing
353 a possible explanation for the referred pain and head sensations described by many of our
354 participants. Moreover, loud noises can trigger painful episodes in individuals with trigeminal
355 neuralgia suggesting that the auditory and trigeminal pathways share anatomy [11]. These
356 symptoms are also consistent with the related tonic tensor tympani syndrome, wherein TTM
357 myoclonus triggers pain within and around the ear and other otologic symptoms by irritating the
358 trigeminal nerve, increasing tympanic membrane tension, or altering middle ear ventilation [20].
359 Chronic, painful irritation of the trigeminal nerve can lead to central pain sensitization, possibly
360 accounting for elevated CNS gain in individuals with pain hyperacusis, if such a phenomenon
361 exists.

362 Notably, two participants in the present study reported that nerve blockers (e.g.,
363 lidocaine, ambroxol) had an excellent effect (>90% pain relief) on their noxacusis, and ambroxol
364 has extensive evidence supporting its use in treating neuropathic pain in conditions such as
365 trigeminal neuralgia, fibromyalgia, and complex regional pain syndrome [16]. Another
366 participant indicated that Botox injections in the tensor veli palatini muscle had an excellent
367 effect (>90% pain relief). The tensor veli palatini is innervated by the trigeminal motor root and

368 may form a functional unit with the TTM to control middle ear pressure [9]. Taken together with
369 existing theories [1,4,10,12,20,23] and other surveys of pain hyperacusis [21], we feel that our
370 results are most consistent with trigeminal nerve involvement. This hypothesis can be clinically
371 tested in the future using locally administered analgesics such as over-the-counter 4% lidocaine
372 ear drops, a common treatment for pain due to acute otitis media in young children [14].

373

374 *Emotional and Psychosocial Consequences of Severe Sound-Induced Pain*

375 While the psychosocial consequences of hyperacusis are often acknowledged in the
376 literature [8], few studies have focused on the unique considerations of pain hyperacusis [21],
377 and none have invited participants to self-report the areas of greatest concern and impact. Most
378 striking psychosocial consequences reported in this study were the perceived lack of support and
379 empathy from others, persistent social isolation, and reduced physical activity (**Table 2**). All
380 participants reported that people within their social support network do not understand their
381 condition. Of particular concern was that all but one participant indicated that medical and
382 healthcare professionals do not understand their condition. In fact, the three participants that
383 have not tried any interventions for pain relief wrote that they do not trust healthcare
384 professionals to help manage their pain. This is consistent with a recent study that demonstrated
385 inconsistent clinical practices and insufficient education regarding hyperacusis amongst
386 audiologists [7]. In desperation for support and medical advice, many individuals with pain
387 hyperacusis seek counsel on social media. Avoiding healthcare professionals and seeking counsel
388 from non-medical sources complicates the ability to take a structured approach to treatment.

389 The present study shows that individuals with pain hyperacusis try many different types
390 of pharmaceutical and non-pharmaceutical interventions that are often self-prescribed. This

391 unstructured treatment approach makes it difficult to identify the treatments and doses that
392 provide pain relief. With the current approach, it becomes challenging to disentangle the myriad
393 factors that may contribute to the efficacy of a specific treatment. Off-label treatment under
394 professional guidance may help to not only relieve pain for individual sufferers, but to generate
395 consistent protocols and clinical datasets that can be leveraged to study and predict treatment
396 success.

397

398 *Limitations and Future Directions*

399 There is a critical need for improved education and interdisciplinary approaches to
400 clinical care and research regarding pain hyperacusis. Healthcare professionals should consider
401 appropriate interventions to improve quality of life by managing the numerous physical, social,
402 and emotional burdens associated with pain hyperacusis. Ear specialists need to collaborate with
403 behavioral health and pain management to develop individualized care plans for patients. As is
404 evident from this report, a holistic treatment plan that not only targets the source of the pain
405 itself, but also serves to mitigate mental and physical health consequences in this population is
406 required. Further development of clinically relevant animal models of pain hyperacusis will be
407 critical for advancing our understanding of its pathophysiological mechanisms and for
408 facilitating drug development.

409 By design, our participants encompassed a small group of individuals with relatively
410 severe pain hyperacusis, and future work will survey a broader and more diverse subset of
411 individuals who experience sound-induced pain. The wide variety of treatments used by our
412 participants precludes systematic analyses of the interrelationships between individual health-
413 related variables, symptom severity, and treatment outcomes. Moreover, we cannot quantify the

414 exact dosages, timing, or duration of treatment administration. Despite these limitations, this
415 work allowed participants to self-generate the most pertinent features of pain hyperacusis that
416 have the greatest impact on their quality of life, and which should serve as primary treatment
417 endpoints in future studies.

418

419

420 ACKNOWLEDGMENTS

421 This work was supported by the National Institutes of Health National Institute on Deafness and
422 Other Communication Disorders (NIH NIDCD) K01 DC019647 (PI: Jahn). KNJ reports
423 additional support from the Department of Defense Congressionally Directed Medical Research
424 Program and the American Speech-Language-Hearing Foundation. STK reports support from the
425 American Speech-Language-Hearing Association and the Susan and Jim Jerger Research in
426 Audiology Fellowship. MSY reports support from the NIH National Institute of Diabetes and
427 Digestive and Kidney Diseases (NIH NIDDK) R01 DK134893 (PI: Yousuf). KNJ is a member of
428 the Scientific Advisory Board for Hyperacusis Research Ltd. and serves as the scientific advisor
429 for Hyperacusis Central. The authors declare no other conflicts of interests. We thank Marianne
430 Awad for assisting with data collection, our Hyperacusis Patient Advisory Board for insightful
431 discussions, and the participants who generously offered their time to contribute to this work.

432

433 **Data Availability Statement:** The conducted research was not preregistered in an independent,
434 institutional registry. Data and analysis code are available from the corresponding author upon
435 reasonable request and completion of an institutional data transfer agreement.

436 REFERENCES

- 437 [1] Auerbach BD, Rodrigues PV, Salvi RJ. Central Gain Control in Tinnitus and Hyperacusis.
438 *Frontiers in Neurology* 2014;5. doi:10.3389/fneur.2014.00206.
- 439 [2] Baguley DM, Hoare DJ. Hyperacusis: major research questions. *Hno* 2018;66:358–363.
- 440 [3] Burke JG, O’Campo P, Peak GL, Gielen AC, McDonnell KA, Trochim WMK. An
441 introduction to concept mapping as a participatory public health research method.
442 *Qualitative Health Research* 2005;15:1392–1410.
- 443 [4] Flores EN, Duggan A, Madathany T, Hogan AK, Márquez FG, Kumar G, Seal RP, Edwards
444 RH, Liberman MC, García-Añoveros J. A non-canonical pathway from cochlea to brain
445 signals tissue-damaging noise. *Current Biology* 2015;25:606–612.
- 446 [5] Jackson KM, Trochim WMK. Concept Mapping as an Alternative Approach for the
447 Analysis of Open-Ended Survey Responses. *Organizational Research Methods* 2002;5:307–
448 336.
- 449 [6] Jahn KN. Clinical and investigational tools for monitoring noise-induced hyperacusis. *The*
450 *Journal of the Acoustical Society of America* 2022;152:553–566.
- 451 [7] Jahn KN, Koach CE. Hyperacusis Diagnosis and Management in the United States: Clinical
452 Audiology Practice Patterns. *American Journal of Audiology* 2023:950–961.
- 453 [8] Jüris L, Andersson G, Larsen HC, Ekselius L. Psychiatric comorbidity and personality traits
454 in patients with hyperacusis. *International Journal of Audiology* 2013;52:230–235.
- 455 [9] Kierner AC, Mayer R, v. Kirschhofer K. Do the tensor tympani and tensor veli palatini
456 muscles of man form a functional unit?: A histochemical investigation of their putative
457 connections | In cooperation with the Institute of Anatomy 2, University of Vienna, Vienna,
458 Austria. *Hearing Research* 2002;165:48–52.
- 459 [10] Liu C, Glowatzki E, Fuchs PA. Unmyelinated type II afferent neurons report cochlear
460 damage. *Proceedings of the National Academy of Sciences* 2015;112:14723–14727.
- 461 [11] Love S, Coakham HB. Trigeminal neuralgia: Pathology and pathogenesis. *Brain*
462 2001;124:2347–2360.
- 463 [12] Noreña AJ, Fournier P, Londero A, Ponsot D, Charpentier N. An Integrative Model
464 Accounting for the Symptom Cluster Triggered After an Acoustic Shock. *Trends in Hearing*
465 2018;22. doi:10.1177/2331216518801725.
- 466 [13] Parthasarathy A, Bartlett EL, Kujawa SG. Age-related Changes in Neural Coding of
467 Envelope Cues: Peripheral Declines and Central Compensation. *Neuroscience*
468 2019;407:21–31.

- 469 [14] Prasad S, Ewigman B. Use anesthetic drops to relieve acute otitis media pain. *Journal of*
470 *Family Practice* 2008;57:370–373.
- 471 [15] Rosing SN, Schmidt JH, Wedderkopp N, Baguley DM. Prevalence of tinnitus and
472 hyperacusis in children and adolescents: a systematic review. *BMJ Open* 2016;6:e010596.
- 473 [16] Russo MA, Baron R, Dickenson AH, Kern K-U, Santarelli DM. Ambroxol for neuropathic
474 pain: hiding in plain sight? *PAIN* 2023;164:3.
- 475 [17] Trochim W, Kane M. Concept mapping: An introduction to structured conceptualization in
476 health care. *International Journal for Quality in Health Care* 2005;17:187–191.
- 477 [18] Trochim WMK. *An Introduction To Concept Mapping For Planning and Evaluation.*
478 *Evaluation and Program Planning* 1989;12:1–16.
- 479 [19] Tyler RS, Pienkowski M, Roncancio ER, Jun HJ, Brozoski T, Dauman N, Coelho CB,
480 Andersson G, Keiner AJ, Cacace AT, Martin N, Moore BCJ. A review of hyperacusis and
481 future directions: Part I. Definitions and manifestations. *American Journal of Audiology*
482 2014;23:402–419.
- 483 [20] Westcott M. Hyperacusis-induced Pain: Understanding and Management of Tonic Tensor
484 Tympani Syndrome (TTTS) Symptoms. *J Pain Relief* 2016;05. doi:10.4172/2167-
485 0846.1000234.
- 486 [21] Williams ZJ, Suzman E, Woynaroski TG. A Phenotypic Comparison of Loudness and Pain
487 Hyperacusis: Symptoms, Comorbidity, and Associated Features in a Multinational Patient
488 Registry. *American Journal of Audiology* 2021;30:1–18.
- 489 [22] Wood MB, Nowak N, Fuchs PA. Damage-evoked signals in cochlear neurons and
490 supporting cells. *Front Neurol* 2024;15:1361747.
- 491 [23] Wu JS, Vyas P, Glowatzki E, Fuchs PA. Opposing expression gradients of calcitonin-related
492 polypeptide alpha (Calca/Cgrp α) and tyrosine hydroxylase (Th) in type II afferent neurons
493 of the mouse cochlea. *Journal of Comparative Neurology* 2018;526:425–438.
- 494

495 FIGURE LEGENDS

496 **Figure 1.** Schematic depicting three potential noxacusis mechanisms. In each model,
497 hypothesized components mediating noxacusis are highlighted in red. (A) In the middle ear
498 model, nociceptive signaling is mediated by the mandibular branch of the trigeminal nerve.
499 Trigeminal nerve afferents innervate the tensor tympani and the tensor veli palatini muscles, both
500 proximal to the middle ear space. (B) In the inner ear model, Type II-afferent nerve fibers
501 synapse with outer hair cells and transduce nociceptive signals to the central auditory system. (C)
502 In the central auditory system, maladaptive hyperactivity in the brainstem and brain potentially
503 mediate hyperacusis.

504

505 **Figure 2.** A) Schematic of pain locations and descriptors reported during the focus group and the
506 percentage of participants who endorsed (B) neuropathic pain and (C) referred pain. Statement
507 numbers are displayed on the y-axis along with a key word or phrase representing the content of
508 the statement. Full statements are listed in Table 2.

509

510 **Figure 3.** The percentage of participants who endorsed (A) otologic symptoms and (B) sensory
511 sensitivities other than pain. Statement numbers are displayed on the y-axis along with a key
512 word or phrase representing the content of the statement. Full statements are listed in Table 2.

513

514 **Figure 4** The percentage of participants who endorsed a lack of empathy or support from others.
515 Statement numbers are displayed on the y-axis along with a key word or phrase representing the
516 content of the statement. Full statements are listed in Table 2.

517

518 **Figure 5.** The percentage of participants who endorsed (A) isolation and reduced physical
519 activity and (B) mental health consequences. Statement numbers are displayed on the y-axis
520 along with a key word or phrase representing the content of the statement. Items with an asterisk
521 were rated on a Likert scale ranging from *Strongly Disagree* to *Strongly Agree*. Full statements
522 are listed in Table 2.

523

524 **Figure 6.** The percentage of participants who tried pharmaceutical or non-pharmaceutical
525 interventions (left panel), the number of therapies tried (middle panel), and the general perceived
526 effectiveness of each type of intervention (right panel).

1 TABLES

2 Table 1. Prevalence of self-reported co-morbid conditions. Thirty-one participants responded to
3 the audiovestibular, neurological, and mental health questions. Chronic pain syndromes and
4 other sensory sensitivities were included in the follow-up survey and thus had 24 total
5 respondents.

Condition	Prevalence
<i>Audiovestibular</i>	
Tinnitus	96.77% (<i>n</i> = 30)
Difficulty hearing in noise	38.71% (<i>n</i> = 12)
Imbalance or dizziness	29.03% (<i>n</i> = 9)
Hearing loss	25.81% (<i>n</i> = 8)
Phonophobia	19.35% (<i>n</i> = 6)
Misophonia	16.13% (<i>n</i> = 5)
Chronic otitis media	9.68% (<i>n</i> = 3)
Central auditory processing disorder	6.45% (<i>n</i> = 2)
<i>Neurological / Mental Health</i>	
Anxiety	48.39% (<i>n</i> = 15)
Depression	25.81% (<i>n</i> = 8)
Head injury	19.35% (<i>n</i> = 6)
Post-traumatic stress disorder	19.35% (<i>n</i> = 6)
Chronic migraine	19.35% (<i>n</i> = 6)
Attention deficit hyperactivity disorder	9.68% (<i>n</i> = 3)
Autism spectrum disorder	6.45% (<i>n</i> = 2)
William's syndrome	0.00% (<i>n</i> = 0)
<i>Chronic Pain Syndromes</i>	
Temperomandibular joint disorders	29.17% (<i>n</i> = 7)
Trigeminal neuralgia	4.17% (<i>n</i> = 1)
Fibromyalgia	4.17% (<i>n</i> = 1)
Traumatic peripheral nerve injury	4.17% (<i>n</i> = 1)
Complex regional pain syndrome	0.00% (<i>n</i> = 0)
Diabetic or other metabolic neuropathy	0.00% (<i>n</i> = 0)
Autoimmune disorders	0.00% (<i>n</i> = 0)
<i>Other Sensory Sensitivities</i>	
Sight	41.67% (<i>n</i> = 10)
No other sensory sensitivities	37.50% (<i>n</i> = 9)
Touch	16.67% (<i>n</i> = 4)
Smell	16.67% (<i>n</i> = 4)
Taste	4.17% (<i>n</i> = 1)

Table 2. The 17 clusters and the individual statements within each cluster. The average rating and the standard deviation of the ratings for each cluster are in parentheses next to the cluster title. The average rating for each statement and the percentage of participants who endorsed each statement are in parentheses next to each statement. Clusters and statements are ordered from highest to lowest average rating.

Concept	Statements
Lack of Empathy or Support from Others (4.21, 0.62)	S84 Medical and healthcare professionals do not understand my hyperacusis symptoms. (4.65, 96.15%)
	S86 Family and friends do not understand my hyperacusis symptoms. (3.77, 100%)
Isolation and Reduced Physical Activity (4.03, 0.81)	S82 My lifestyle has changed considerably since the onset of my pain hyperacusis. (5.00, 100%)
	S92 I have become isolated due to my hyperacusis. (4.77, 100%)
	S34 I feel I must control the environment around me to reduce my hyperacusis symptoms. (4.69, 100%)
	S56 My sound-related pain handicaps me. (4.35, 88.46%)
	S25 I avoid leaving the house due to my hyperacusis. (3.92, 96.15%)
	S40 I spend time in silence. (3.54, 100%)
	S42 I avoid exercise or physical activity due to my hyperacusis. (3.15, 92.31%)
Symptom Setbacks (3.69, 0.89)	S66 My sound-related pain makes it difficult for me to speak. (2.81, 84.62%)
	S81 The longer I am exposed to sound, the worse my hyperacusis symptoms become. (4.77, 100%)
	S87 My hyperacusis gradually became worse over time. (4.19, 88.46%)
	S13 My sensitivity to sound increases after exposure to a loud sound. (3.96, 100%)
	S57 Each of my hyperacusis setbacks lasts longer than the one before. (2.85, 100%)
Mental Health Consequences (3.64, 0.53)	S77 Setbacks permanently worsen my pain hyperacusis. (2.69, 80.77%)
	S22 I feel trapped by hyperacusis. (4.35, 96.15%)
	S21 I feel grief because of hyperacusis. (3.73, 92.31%)
	S27 My hyperacusis makes me feel depressed. (3.35, 88.46%)
Pain Triggers, Severity, and Time Course (3.47, 0.84)	S18 I feel lonely. (3.15, 92.31%)
	S85 Certain types of sounds (e.g., high pitched, low pitched) cause me more pain than others. (4.81, 100%)
	S91 My sound-related pain is chronic. (4.69, 100%)
	S75 Loudness affects my level of pain. (4.42, 96.15%)
	S15 I am sensitive to electronic sounds. (3.65, 96.15%)
	S68 My sound-related pain is severe. (3.35, 96.15%)
	S69 My sound-related pain is unmanageable. (3.19, 92.31%)
	S67 My pain makes it difficult for me to tolerate even quiet sounds, like a keyboard or the hum of a refrigerator. (3.15, 92.31%)
	S65 My pain in response to sound is delayed. (3.00, 80.77%)
	S64 My pain occurs immediately after a sound. (2.96, 84.61%)
Control and Avoidance Behaviors (3.35, 1.21)	S30 My own voice is unbearable to me. (2.46, 84.62%)
	S62 Wearing in-the-canal hearing protection is painful. (2.42, 88.46%)
	S19 I must plan to avoid exposure to intolerable sounds. (4.58, 100%)
	S01 Hearing protection devices help me. (4.08, 96.15%)
	S10 Sounds I can control (e.g., my own music, my own voice) are easier to tolerate than sounds I cannot control (e.g.,

		ambulance, other people laughing, dogs barking). (3.38, 84.62%)
	S09	I wear hearing protection devices. (3.35, 96.15%)
	S32	White noise helps to improve my hyperacusis symptoms. (1.38, 23.08%)
Pain Laterality (3.26, 0.71)	S71	My sound-related pain affects both ears. (3.69, 80.77%)
	S02	My hyperacusis symptoms are worse in one ear than the other. (3.62, 88.46%)
	S60	My sound-related pain is worse on one side than the other. (3.54, 84.62%)
	S72	My sound-related pain affects only one ear. (2.19, 46.15%)
Emotional Reactions to Sound (3.10, 0.16)	S38	I become tense when I am exposed to sounds. (3.31, 88.46%)
	S28	My hyperacusis makes me feel anxious. (3.23, 88.46%)
	S26	I feel overwhelmed by sound. (3.15, 88.46%)
	S08	Sounds exhaust me. (3.12, 76.92%)
	S24	I startle easily. (3.08, 76.92%)
	S41	I am afraid of sound. (2.96, 73.08%)
	S06	I experience negative emotional reactions to sounds (e.g., anger, annoyance, frustration). (2.85, 69.23%)
Symptom Onset (2.95, 1.23)	S79	My hyperacusis symptoms began or became worse due to acoustic trauma (noise exposure). (4.35, 88.46%)
	S88	My pain hyperacusis began as loudness hyperacusis. (3.58, 76.92%)
	S89	My hyperacusis began suddenly. (3.54, 76.92%)
	S83	My hyperacusis symptoms began or became worse due to exposure to an ototoxic drug/chemical. (1.81, 30.77%)
	S80	My hyperacusis symptoms began or became worse due to a head injury. (1.50, 23.08%)
Neuropathic Pain (2.87, 0.79)	S50	I feel pain in or near my ear(s) when exposed to sound. (4.04, 92.31%)
	S52	My sound-related pain feels like a burning sensation. (3.08, 80.77%)
	S53	My sound-related pain feels like a stabbing sensation. (2.88, 76.92%)
	S70	My sound-related pain is throbbing. (2.38, 73.08%)
	S54	My sound-related pain feels like a pinching sensation. (1.96, 53.85%)
Fluctuating Severity (2.78, 0.77)	S33	White noise makes my hyperacusis symptoms worse. (3.69, 84.62%)
	S59	My pain levels fluctuate. (3.38, 96.15%)
	S58	The type or severity of my sound-related pain fluctuates. (2.85, 88.46%)
	S74	I cannot tell where my sound-related pain is coming from. (2.04, 65.38%)
	S17	My hyperacusis symptoms get worse whenever I have a cold, sinus infection, or allergies. (1.96, 50.00%)

Otologic Symptoms [Non-pain] (2.64, 0.92)	S04	I experience tinnitus (ringing or noises in the ears or head). (4.69, 96.15%)
	S05	My tinnitus gets worse due to sound (reactive tinnitus). (3.23, 88.46%)
	S12	I feel a pulsating sensation in my ear(s). (2.42, 65.38%)
	S03	I experience fullness or pressure in my ear(s). (2.38, 80.77%)
	S11	I feel a fluttering sensation in my ear(s). (2.23, 80.77%)
	S63	I experience muscle spasms due to my hyperacusis. (2.19, 65.38%)
	S31	I experience 'vibrations' in my ear(s). (2.15, 57.69%)
	S14	I perceive sounds as distorted. (1.81, 46.15%)
Interference with Essential Functions (2.47, 0.54)	S39	My hyperacusis makes it difficult to concentrate. (3.08, 92.31%)
	S90	My hyperacusis has made me lose my appetite. (2.31, 50.00%)
	S43	My hyperacusis interferes with my sleep. (2.04, 73.08%)
Other Sensory Sensitivities (2.34, 0.50)	S23	I experience more than one type of hyperacusis (e.g., pain + loudness/fear/annoyance). (2.96, 69.23%)
	S76	My sound-related pain causes fatigue. (2.85, 80.77%)
	S07	I cannot tell where sounds are coming from. (2.08, 61.54%)
	S29	My hyperacusis disorients me. (2.08, 61.54%)
	S20	I experience other sensory sensitivities (e.g., light, touch, smell, taste). (1.88, 53.85%)
Irritation/Inflammation (2.08, 0.57)	S61	I experience inflammation at or near the site of my sound-related pain. (2.46, 61.54%)
	S16	My ears itch. (2.35, 73.08%)
	S78	I can see redness at or near the site of my sound-related pain. (1.42, 30.77%)
Referred Pain (1.78, 0.21)	S44	I feel pain in my face when exposed to sound. (2.08, 73.08%)
	S49	I feel pain in the side of my head when exposed to sound. (2.04, 57.69%)
	S55	My sound-related pain changes locations. (1.81, 65.38%)
	S51	I feel pain elsewhere in my body when exposed to sound. (1.81, 46.15%)
	S48	I feel pain in the back of my head when exposed to sound. (1.77, 42.31%)
	S46	I feel pain in my throat when exposed to sound. (1.65, 34.62%)
	S45	I feel pain in my neck when exposed to sound. (1.62, 53.85%)
	S47	I feel pain in the front of my head when exposed to sound. (1.46, 30.77%)

Table 3. The number of participants (N) who have tried each pharmaceutical and non-pharmaceutical intervention for pain hyperacusis, along with each intervention's perceived effectiveness.

Intervention	N	Excellent effect (>90% pain relief)	Modest effect (75% pain relief)	Somewhat effective (50% pain relief)	No effect (0% pain relief)	Made my noxacusis worse
<i>Opioid Medications</i>	2					
Oxycodone (including OxyContin)	1	1	0	0	0	0
Other: Tramadol	1	0	0	1	0	0
<i>Non-Opioid Medications</i>	17					
Benzodiazepenes (e.g., clonazepam, alprazolam)	10	1	2	2	4	1
Antidepressants (e.g., clomipramine, amitriptyline, duloxetine)	9	0	0	2	7	0
NSAIDS (e.g., ibuprofen, naproxen)	8	0	0	5	3	0
Muscle relaxants (e.g., baclofen, cyclobenzaprine)	6	0	0	2	7	0
Anticonvulsants (e.g., gabapentin, pregabalin, carbamazepine)	6	1	1	2	2	0
Nerve blockers (e.g., lidocaine, ambroxol)	4	2	0	0	2	0
Botox*	1	1	0	0	0	0
Other: Tylenol	2	0	1	1	0	0
Other: Flunarizine	1	0	0	0	1	0
Other: Valacyclovir	1	0	0	1	0	0
<i>Cannabinoids (marijuana, THC, and/or CBD)</i>	10	0	0	0	9	1
<i>Non-pharmaceutical Interventions</i>	20					
Meditation, yoga, or mindfulness therapy	12	0	0	1	11	0
Counseling	11	0	0	1	10	0
Cognitive behavioral therapy	9	1	0	1	7	0
Sound therapy	8	1	1	0	2	4
Tinnitus retraining therapy	5	0	0	0	3	2
Other: Round and oval window reinforcement	1	0	0	0	1	0
Other: Prism lens therapy	1	0	0	1	0	0

Other: Low level laser therapy	1	0	0	1	0	0
Other: Pranic or Energy Healing	1	0	0	1	0	0
Other: TMJ splint therapy	1	1	0	0	0	0
Other: TMJ physical therapy	2	1	0	0	1	0
Other: Chiropractor or massage therapy	2	0	1	1	0	0
Other: Dry needling	1	0	0	0	1	0
Other: Acupuncture	1	0	0	0	1	0
Other: Prayer	1	0	0	0	1	0


NSAIDS: Non-steroidal anti-inflammatory drugs




*Botox was injected into tensor veli palatini muscle.

Middle Ear



Inner Ear

Brain and Brainstem








Sometimes
 About Half the Time
 Most of the Time
 Always




Sometimes
 About Half the Time
 Most of the Time
 Always






Sometimes
 About Half the Time
 Most of the Time
 Always




*Non-pharmaceutical only = 0%


NUMBER OF PHARMACEUTICAL THERAPIES



NUMBER OF NON-PHARMACEUTICAL THERAPIES



GENERAL EFFECTIVENESS: PHARMACEUTICALS



GENERAL EFFECTIVENESS: NON-PHARMACEUTICALS

